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EZH2 is frequently overexpressed in glioblastoma
(GBM), suggesting an oncogenic function that could
be a target for therapeutic intervention. However,
reduced EZH2 activity can also promote tumorigen-
esis, leading to concerns about the use of EZH2 in-
hibitors. Here, we provide further insight about the
effects of prolonged Ezh2 inhibition in glioblastoma
using preclinical mouse models and primary tumor-
derived human GBM cell lines. Using doxycycline-
inducible shRNAs that mimic the effects of a selec-
tive EZH2 inhibitor, we demonstrate that prolonged
Ezh2 depletion causes a robust switch in cell fate,
including significantly enhanced proliferation, DNA
damage repair, and activation of part of the pluripo-
tency network, resulting in altered tumor cell identity
and tumor progression. Short-term Ezh2 depletion
significantly improved survival without the tumor
progression observed upon prolonged Ezh2 deple-
tion, suggesting that precise dosing regiments are
very important. These results could be of high clinical
relevance with regard to how glioblastomas should
be treated with epigenetic therapies.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and dead-
liest primary brain tumor in human adults, and new therapies are
urgently required to improve survival rates for GBM patients.
In addition to genetic alterations, epigenetic dysregulation
also contributes to cancer (Baylin and Jones, 2011; Sparmann
and van Lohuizen, 2006), and hence, epigenetic-based thera-
pies are being investigated for cancer treatment. The Polycomb
group protein EZH2 is the catalytic component of the PolycombCrepressive complex PRC2 and acts mainly through trimethyla-
tion of histone H3 lysine27, which is associated with transcrip-
tional repression (Margueron and Reinberg, 2011). EZH2 over-
expression has been reported in GBM (Li et al., 2013; Suva`
et al., 2009; Orzan et al., 2011; Crea et al., 2010) and various
other cancer types and is often correlated with metastases
and poor prognosis (reviewed in Chase and Cross, 2011;
Simon and Lange, 2008). Based on its aberrant upregulation
in several types of cancer, EZH2 is suggested to act as an
oncogene and hence is an attractive candidate target for ther-
apeutic intervention.
Intriguingly, recent studies have shown that loss of function of
EZH2 can also promote cancer in a context-dependent manner
(Morin et al., 2010; Simon et al., 2012; Ernst et al., 2010). More-
over, recent studies strongly implicated missense mutations
in genes encoding histone H3.3 and H3.1 in pediatric glioblas-
tomas, resulting in reduced H3K27me3 levels (Lewis et al.,
2013; Chan et al., 2013; Bender et al., 2013). Additionally, it
was shown that H3.3K27M mutation dominantly inhibits the
enzymatic activity through interaction with the EZH2 subunit.
Obviously, these data raise concerns about therapeutic strate-
gies that decrease H3K27 methylation in cancer. The context-
dependent effects of EZH2 inhibition signifies for the importance
of testing the effects of EZH2 inhibition in appropriate preclinical
tumor models. Until very recently, there were no specific EZH2
inhibitors available for in vivo treatment. To better understand
the role of EZH2 in high-grade glioma, we have therefore devel-
oped an in vivo approach that mimics the inhibitory function of a
selective EZH2 inhibitor. Intriguingly, prolonged Ezh2 depletion
in high-grade gliomas switches tumor cells to a different epige-
netic state that significantly changes tumor cell identity and re-
sults in tumor progression. These results demonstrate that the
effect of EZH2 inhibition depends on well-balanced drug admin-
istration schedules in a cell context-dependent manner, which
might have important consequences for the clinic with regard
to howGBMpatients should be treatedwith epigenetic therapies
such as EZH2 inhibition.ell Reports 10, 383–397, January 20, 2015 ª2015 The Authors 383
RESULTS
Ezh2 Knockdown Reduces Proliferation and Induces
Dedifferentiation in Glioma-Initiating Cells
First we assessed the effect of inducible Ezh2 knockdown on
the proliferative capacity of glioblastoma-initiating cells (GICs;
see Figure 1A and Experimental Procedures). Importantly, the
molecular signature Ink4a/Arf/-EGFRvIII closely resembles
the classical subtype in human GBM, whereas the p53/
-Ink4a/Arf/-KRasV12 signature mirrors the proneuronal sub-
type (Verhaak et al., 2010; Friedmann-Morvinski et al., 2012;
de Vries et al., 2010). Three different doxycycline (dox)-inducible
shRNAs were used to target the Ezh2 gene in p53/-Ink4a/Arf/
-KRasV12 GICs, resulting in inhibition of cell proliferation when
compared with controls (Figures 1B, 1C, and S1A). Ezh2 knock-
down correlated with decreased H3K27me3 levels (Figure 1D).
Upon dox removal, Ezh2 knockdown was reverted, resulting in
Ezh2 expression levels comparable to control cells (Figure S1B).
These data were confirmed by using Ink4a/Arf/-EGFRvIIIGICs
(Figure S1C) as well as by glioblastoma cancer ‘‘stem-like’’ cells
(GSCs) isolated from spontaneously derived glioblastomas
(Figure S1D).
Given the important role of Ezh2 in maintaining the balance of
self-renewal and differentiation in neural stem cells (NSCs)
(Sher et al., 2008), we investigated whether Ezh2 knockdown
in GICs would result in an increased differentiation potential
and consequently in reduced growth capacity. However, we
did not observe differentiation into astrocytes or neurons upon
Ezh2 knockdown. We detected reduced protein levels of the
astrocyte marker GFAP, whereas levels of the neuronal stem
cell marker nestin were retained (Figure 1D). Next, we tested
the differentiation capacity of GICs in serum-containing medium
and found that they readily differentiated into astrocytes
(predominantly) and neurons (Figure S1E). Additionally, p53F/F-
Ink4a/ArfF/F-KRasV12F/F (WT) NSCs ceased proliferation upon
Ezh2 depletion, and the few cells that survived adapted
to a differentiated morphology (Figure S1F), excluding the
possibility that these GICs have an impaired differentiation
capacity.
Next, we performed cell-cycle analysis and noticed a signifi-
cant increase in G0/G1 phase and a small, although not signifi-
cant, decrease in S phase between Ezh2 knockdown and control
GICs (Figure 1E), suggesting a reduced or delayed replication
potential upon Ezh2 knockdown. No significant changes in
apoptosis levels were observed using Annexin V staining (data
not shown).
Interestingly, in contrast to the controls, Ezh2-depleted GICs
showed a morphology conversion accompanied by the appear-
ance of small cell clusters (Figure 2A). Under embryonic stem cell
(ESC) conditions, Ezh2-depleted GICs rapidly formed ESC-like
colonies that stained positive for alkaline phosphatase (AP) (Fig-
ure 2B). These colonies could be picked and further cultured
while maintaining an ESC-like morphology (Figure 2C). More-
over, Ezh2-depleted GICs also showed increased expression
of the ESC marker SSEA1 (Figure S2A). Ezh2-depleted and con-
trol GICswere also directly cultured in stringent serum-free 2i-ES
conditions (Silva et al., 2008), with or without dox treatment.
Within 2 days, Ezh2-depleted GICs showed development of384 Cell Reports 10, 383–397, January 20, 2015 ª2015 The Authorssmall cell clusters, which grew out to bigger colonies within
several days. This is in contrast to control GICs that went into
apoptosis (Figure S2B). Inhibition of Ezh2 enzymatic activity
without dissociation of the Ezh2 complex was accomplished
by treating GICs with the Ezh2 inhibitor GSK343 and also re-
sulted in an altered morphology and prominent appearance of
alkaline phosphatase (AP)-positive colonies (Figures 2D, 2E,
and S2C). Altogether, Ezh2 depletion in GICsmodifies their plas-
ticity and proliferation capacity.
Prolonged Ezh2 Depletion in High-Grade Gliomas
Results in Escape of Initial Growth Reduction and Tumor
Progression
We next investigated the in vivo effect of Ezh2 depletion on tu-
mor-initiating capacity by treating mice with dox 4 days before
injection of GICs (GICs did not receive dox in vitro) until the
end of the experiment (Figure 3A). To mimic the effect of a selec-
tive Ezh2 inhibitor, dox treatment was started after appearance
of a full blown tumor (Figures 3A and 3B). In both instances,
Ezh2 knockdown in mouse glioblastoma resulted in significantly
prolonged survival compared with controls (Figure 3C). These
results were confirmed by in vivo studies using two other inde-
pendent Ezh2 hairpins (Figure S3A) and by Ezh2 knockdown in
glioblastomas that arose from the Ink4a/Arf/-EGFRvIII signa-
ture (Figure S3B). Ezh2 knockdown in tumors, isolated at the
endpoint of the experiment, was at least 80% as shown by west-
ern blot, quantitative real-time PCR, and immunohistochemistry
for Ezh2 (Figures 3D–3F). mRNA levels of other PRC2 members
(e.g., Suz12, Eed, and Ezh1) or the PRC1 component Bmi1
remained unaltered (Figure S3C). Interestingly, although Ezh2
depletion in glioblastoma initially slows down tumor growth, we
observed that this effect was only temporary as tumors invari-
ably escaped arrest and then significantly progressed with a
faster growth rate than the control tumors (Figures 4A, insert,
and S4A). Similar results were seen for glioblastomas where
Ezh2 depletion was started at day 18 (data not shown). High pro-
liferation rates in Ezh2-depleted ‘‘escaper’’ tumors compared
with control tumors were confirmed with increased Ki67 levels
(Figure 4C). This increase in proliferation could not be explained
by outgrowth of tumor cells with lower levels of Ezh2 knockdown
since the tumors maintained Ezh2 depletion (Figures 3D–3F).
Additionally, we also performed a time-controlled experiment
where we isolated both control and Ezh2 KD tumors after 10,
20, and 35 days and at the endpoint of the experiment (Fig-
ure S4B). Ki67 immunohistochemical staining for these time
points clearly demonstrates that Ezh2-depleted tumors are
initially less proliferative at 10 and 20 days after GIC injection
compared with control tumors, which correlates with the initial
observed reduced growth and increased survival upon Ezh2
depletion. However, when Ezh2-depleted tumors escape their
growth arrest (on average at day 20, though there is obvious
variation between individual tumors), they clearly become more
proliferative as compared with control tumors, even though
they are much smaller at that time than control tumors (Fig-
ure S4B). This proliferation phenotype is depended on prolonged
Ezh2 depletion, as shown in Figure S4C. Control tumors
were determined by pathology as malignant gliomas with
increased cellularity, (pseudopalisading) necrotic areas, mitosis,
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Figure 1. Ezh2-Depleted GICs Have a Decreased Proliferation Capacity
(A) Mouse GICs and GSCs with known genetic signatures were transduced with a lentiviral dox-inducible shRNA-mediated construct (shEzh2_1-3 or shGFP) and
FACS sorted for GFP.
(B) Phase contrast images of control (shGFP) and Ezh2 KD GICs (p53/;Ink4a/Arf/;KRasV12) with or without dox treatment for 5 days.
(C) Growth curves of Ezh2-depleted and control GICs (error bars represent the SDs, n = 2).
(D) Western blot analysis of Ezh2, H3K27me3, Nestin and GFAP in GICs after 5 days with or without dox treatment.
(E) Cell-cycle analysis (bromodeoxyuridine/propidium iodide [BrdU/PI]) of control (shGFP) and Ezh2 KD GICs after 5 days of dox treatment (*p = 0.023, ns = not
significant). Error bars represent the SDs (n = 3).
See also Figure S1.vascularity, hemorrhage, and multinucleated giant cells (Fig-
ure S4D). Intriguingly, Ezh2-depleted escaper tumors showed
a vastly different phenotype with highly mitotic and pleomorphicCtumor cells that tend to group together (Figures 4B and S4E).
Moreover, although some GBM histopathological characteris-
tics, such as pseudopalisading necrosis, could be observed,ell Reports 10, 383–397, January 20, 2015 ª2015 The Authors 385
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Figure 2. Induced Plasticity in GICs upon Reduced Ezh2 Activity
(A) Phase-contrast images of Ezh2-depleted and control GICs after 5 days of dox treatment under NSCs conditions. Arrows indicate appearance of small cell
clusters.
(B) Phase contrast images and alkaline phosphatase (AP) staining of control and Ezh2-depleted GICs with appearance of ESC-like colonies in Ezh2-depleted
GICs in ES conditions (seeded on laminin-coated plates in serum-free NSC medium and switched after 5 days to ES conditions for 3 days).
(C) Colonies picked from Ezh2-depleted GICsmaintain their ESC-like morphology upon subsequent culturing (shown is passage 4 on gelatin-coated plates in ES
conditions).
(D) Phase-contrast images of shGFP and shEzh2 GICs treated with or without dox (100 ng/ml) or Ezh2 inhibitor GSK343 (1 mM) for 5 days under NSCs conditions
(seeded on pO-laminin coated plates in NSC medium) and subsequently switched to ES conditions for 3 days.
(E) AP staining of ESC-like colonies in shGFP and shEzh2 GICs treated with dox or GSK343 (1 mM).
See also Figure S2.
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Figure 3. Ezh2 Knockdown in Glioblastoma Initially Reduces Growth
(A) Validation of Ezh2 depletion in vivo using NOD-SCIDmice that are intracranially injected with shGFP or shEzh2 transduced Ink4a/Arf/,p53/,KRasV12GICs.
The panel shows a schematic presentation of the two experimental groups. To investigate the role of Ezh2 in tumor developmentmice received dox 4 days before
injection until the end of the experiment (green). To study the role of Ezh2 in tumor maintenance, dox treatment was started at day 18 after injection when a
developing tumor was demonstrated by at least three consecutive time points of bioluminescence imaging (red).
(B) Noninvasive monitoring of high-grade glioma development by the Luciferase Reporter. Shown are representative bioluminescence images (photons/second)
1 day, 1 week, and 2 weeks after intracranial injection of GICs.
(C) Kaplan-Meier survival curves of Ezh2 KD in high-grade gliomas. In green, Ezh2 KD (shEzh2+dox started at day 0 after injection, n = 26) compared with controls
(shGFP +dox, n = 16). In red, Ezh2 KD (shEzh2 + dox started at day 18 after injection, n = 15) is compared with controls (untreated shEzh2, n = 4). p values were
determined by log-rank test (Mantel-Cox).
(D) Western blot analysis of Ezh2 KD tumors compared with control tumors. Tumors were isolated at the endpoint of the experiment.
(E) qRT-PCR of Ezh2 in Ezh2-depleted glioblastomas treated with dox at day 0 or 18 days after injection. Data are normalized to HPRT and relative to control
tumors (average of n = 3). Error bars represent SDs for two independent primer sets.
(F) Immunohistochemical staining for H&E, GFP, and Ezh2 in Ezh2 KD and control tumors.
See also Figure S3.
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Ezh2-depleted escaper tumors were characterized as undiffer-
entiated tumors reflecting epithelial characteristics.
Next, we performed immunohistochemical stainings for differ-
entiation markers on control and Ezh2-depleted tumors (Fig-
ure 4D). Similar to our in vitro results, we observed no GFAP in
Ezh2-depleted tumors in contrast to the untreated tumors with
normal Ezh2 expression. GFAP-positive cells were only detected
in the rim surrounding the tumor, which is also observed in hu-
man GBM and represent reactive astroglia that are migrating
to the tumor. Furthermore, Ezh2-depleted escaper tumors
stained negative for S100 and TuJ and were Nestin positive,
whereas the control tumors were positive for S100 and TuJ.
No caspase 3-positive cells could be detected in Ezh2-depleted
tumors and only very few in control tumors (data not shown),
indicating that the growth arrest upon Ezh2 depletion is not
caused by increased differentiation or apoptosis.
We next examined the effects of short-term versus long-term
Ezh2 depletion on tumor progression. Short-term Ezh2 depletion
(for 16 days) significantly improved survival when compared
with prolonged Ezh2 depletion (until time of death; Figure 4E).
Moreover, short-term Ezh2 depletion did not result in the
‘‘escaperphenomenon’’ accompaniedwith increasedproliferation
observed upon prolonged Ezh2 depletion (Figure 4E). In conclu-
sion, these data demonstrate that in contrast to short-term Ezh2
depletion, prolonged Ezh2 depletion in glioblastoma invariably re-
sults in an epigenetic phenotypic switch yielding highly prolifera-
tive and undifferentiated tumors, resulting in tumor progression.
Robust Epigenetic Switch in Glioblastomas upon
Prolonged Ezh2 Depletion Partially Activates
Pluripotency Network
Next, we performed a global RNA-seq of Ezh2 knockdown
versus control tumors. Ezh2 mRNA levels confirmed stable
Ezh2 knockdown (68%–84%) in Ezh2-depleted tumors (Fig-
ure S5A). Upon Ezh2 depletion, many genes are significantly
(p < 0.01) differentially expressed, and gene expression patterns
are consistent across individual tumors (Figures 5A–5C). A sig-
nificant proportion of genes enhanced upon Ezh2 depletion is
among the gene ontology categories related to cell morphology,
(embryonic) development, and cell proliferation (Figure 5D),
whereas downregulated genes are associated with nervous sys-
tem development and differentiation, neurogenesis, adhesion,
and apoptosis (Figure S5B).Figure 4. Prolonged Ezh2 Depletion in Glioblastoma Leads to a Drasti
erative Tumors
(A) The median of tumor growth as measured by noninvasive bioluminescence im
tumor development (error bars represent the interquartile range). Insert shows larg
arrow) (larger spread at later time points is caused by variance in the amount of tu
Ezh2-depleted tumors at the time of death is significantly different (p = 0.035, as
(B) Histological analysis (H&E) of Ezh2-depleted and control glioblastomas. Dep
(C) Ki67 staining of Ezh2-depleted and control tumors (left) isolated at the time o
t test using three samples per experimental group (right). Error bars represent th
(D) Immunohistochemical analysis of Ezh2, GFAP, S100, TuJ, and Nestin in Ezh2
(E) Kaplan-Meier survival curves (left) and average tumor growth (middle) of Ezh2-
with prolonged Ezh2-depleted tumors (Ezh2 depletion started after GIC injection u
death; p values were determined by log-rank test (Mantel-Cox). Error bars repre
long-term Ezh2-depleted tumors is shown (right). Tumors are isolated at day 30
See also Figure S4.
CMany genes enriched upon Ezh2 depletion in glioblastoma
were involved in pluripotency. We therefore closely looked at
a panel of pluripotency-associated genes (see Table S1) and
found that a subset (22%, 26 of 117) was significantly enhanced
more than 1.5-fold in at least six or more Ezh2-depleted tumors
(Figure 5E). Enrichment for Lin28b was validated by qRT-PCR in
Ezh2-depleted tumors and GICs (Figures 5F and S5C). Many
genes involved in mesodermal differentiation were also upregu-
lated upon Ezh2 depletion, which were validated by qRT-PCR
(Figures S5D and S5E). Notably, enhanced expression of
SNAI1 and MEOX2 in glioma patients is correlated with poor
survival (Figure S5F). Furthermore, gene expression levels of
many mesenchymal markers, like Vimentin, N-cadherin (Cdh2),
Fibronectin, Collagen, Integrins, and MMP9 were also reduced
in Ezh2-knockdown glioblastomas (Figure 5G). This effect was
accompanied by upregulation of epithelial markers such as
Occludin and Claudin 3, Claudin 7, and Claudin 10. To gain
further insight in Ezh2 knockdown-mediated pluripotency in
the escaper tumors, we isolated GSCs from these Ezh2-
depleted tumors and cultured those in NSC conditions with or
without doxycycline (Figure 5H). Ezh2-depleted GSCs showed
a different morphology relative to their Ezh2-positive controls
and started to grow in clusters that resembled epithelioid cells,
which stained positive for the ESC marker AP (Figure 5H). As
shown in Figure 5I, after only 3 days of culture in ESC conditions,
ESC-like colonies developed from GSCs that were isolated
out of Ezh2-depleted tumors and that continued to grow in the
absence of Ezh2 in vitro (note that no exogenous reprogramming
factor genes were introduced). These colonies could be further
cultured while maintaining an ESC-like morphology and stained
positive for AP and the pluripotency marker nanog (Figures 5I
and 5J, respectively). However, nanog expression levels were
lower when compared with ESCs (Figure S5G). In contrast, no
ESC-like colonies were observed in Ezh2-positive GSCs, and
these cells ceased proliferation after several days under ES con-
ditions. Overall, these results suggest that GSCs profit from Ezh2
depletion-mediated epigenetic switching, due to enhanced
expression programs that are normally not observed in neural
lineages. Interestingly, these effects are reversible when Ezh2
levels are restored (Figures 5H and 5I). Ultimately, after an initial
growth arrest upon Ezh2 depletion, escaper tumor cells reset
their epigenetic gene expression profile, resulting in a changed
tumor cell identity.c Epigenetic Switch, Resulting in Undifferentiated and Highly Prolif-
aging is shown for Ezh2 KD (n = 26) and control mice (n = 16) from the start of
er scale of tumor growth to illustrate the tumor escape phenotype (indicated by
mor outgrowth between individual tumors). Tumor growth between control and
determined by Mann-Whitney U test).
icted are two representative examples from each experimental group.
f death and about the same size. Significance was determined by an unpaired
e SD.
KD and control glioblastomas, representative for all tumors.
depleted tumors for 16 days after GIC injections (short-term, n = 10) compared
ntil time of death, n = 8). Control tumors (shGFP, n = 5) received dox until time of
sent represent the SD. Moreover, Ki67 and Ezh2 staining of short-term versus
and day 40 after intracranial injection.
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Enhanced DNA Damage Repair upon Prolonged Ezh2
Knockdown in Glioblastomas
One of the prominent enhanced gene ontology categories in
Ezh2-depleted glioblastomaswasDNA repair.We therefore spe-
cifically investigated expression profiles of well-known DNA
repair genes and found that they were significantly enriched as
determined by GSEA (p < 0.0001; see Table S2). Of the DNA
repair genes, 28% (47 of 166) were enhanced more than 1.5-
fold in at least five or more tumors upon Ezh2 knockdown (Fig-
ure 6A). Remarkably, 43% (p < 0.0001) of these upregulated
DNA repair genes are directly involved in homologous recombi-
nation (HR), such as Rad51, Rad54, Rad17, Rbbp8, Xrcc2,
Brca2, and PCNA (Figure 6B). HR is important in the repair of
DNAdouble-strandbreaks (DSBs) that canbe triggeredbyg-irra-
diation, oxidative stress, and chemotherapeutic treatment. Since
Rad51 is a critical component of the DNA DSB repair pathway
by promoting strand exchange at the site of damaged DNA, we
performed immunohistochemical stainings for Rad51. Ezh2-
depleted tumors stained significantly more positive for Rad51
compared with control tumors (Figure 6C). Furthermore, Rad51
mRNA levels were up to 6-fold higher, as were Rad51 protein
levels (Figure 6C). Ezh2-depleted tumors were also less positive
forg-H2AX, a sensitivemarker forDNADSBs (Figure 6D), demon-
strating a correlation between higher Rad51 levels and increased
repair of DSBs upon loss of Ezh2. Additionally, we studied the ef-
fect of Ezh2 knockdown on Rad51 levels in GICs. Rad51 mRNA
levels were upregulated in Ezh2-depleted GICs, which have a
reduced growth proliferation, indicating that Rad51 overexpres-
sion is directly linked to loss of Ezh2 (Figure 6E).
Enhanced DNA Damage Repair Attenuates TMZ
Treatment in Human GBM
Temozolomide (TMZ) is the only standard chemotherapeutic
drug used for the treatment of GBM patients (Stupp et al.,
2005). This agent methylates the O6 position on guanine, and
O6-methylguanine-induced cell death is critically dependent on
the formation of DSBs (Roos et al., 2009). We therefore assessed
the effect of Ezh2 depletion in TMZ-treated GICs and tumors.
Ezh2-depleted GICs were less sensitive to TMZ treatment
and did not change their morphology in contrast to control
GICs that were more sensitive to TMZ treatment, resulting inFigure 5. Activation of Partial Pluripotency Network Modifies Tumor C
Global gene expression changes in glioblastoma upon Ezh2 KD (shEzh2 dox-tre
(A) Scatter plot comparing global gene expression levels between control (mean o
Significantly (p < 0.01) upregulated genes in Ezh2-depleted tumors compared wit
are shown in green. Upon Ezh2-depletion 202 and 780 genes areR1.5-fold upr
(B) Heatmap showing per-sample expression values of differentially expressed g
(C) Correlation plot between the global expression profiles of Ezh2-depleted and
(D) Gene ontology represents biological processes enhanced upon Ezh2 KD in g
(E) The most enriched pluripotency-associated genes upon Ezh2-depletion in gli
(F) qRT-PCR validation of Lin28b expression levels in control (n = 2) and Ezh2-d
(G) Differentially expressed mesenchymal and epithelial genes in Ezh2-depleted
(H) Phase-contrast images and AP staining of GSCs isolated from two represen
GSCs were isolated from malignant gliomas and cultured on laminin-coated plat
control for AP staining (insert).
(I) Phase-contrast images and AP staining of ESC-like colonies observed in Ezh2
protein levels in GSCs treated with or without dox in NSC (N) and ES (E) conditio
(J) Nanog staining of ESC-like colonies in Ezh2-depleted GSCs. ESCs were used
See also Figure S5.
Cdramatic shape changes and increased cell death (Figure 7A).
Next, we performed an in vivo experiment wherein Ezh2-
depleted and control tumors were treated with or without TMZ.
Treatment was started at day 9 after injection, when growing
tumors were identifiable with bioluminescence imaging. As ex-
pected, TMZ significantly increased survival (shGFP+dox versus
shGFP+dox+TMZ; Figure 7B, left). However, Ezh2 knockdown
attenuated the effect of TMZ treatment observed in the control
tumors (Figure 7B). This difference in response to TMZ treatment
is also illustrated by tumor growth in Figures 7B (right) and S6A.
In addition, elevated Rad51 levels in Ezh2-depleted tumors
treated with TMZ relative to the TMZ-treated control tumors
implicate that the tempered effect in survival might be a result
of TMZ chemoresistance due to Ezh2-mediated enhanced
DNA repair (Figure 7C). We next examined the effect of EZH2
inhibition in seven human GBM lines, including three human
glioblastoma stem cell lines derived from freshly isolated primary
tumors under optimal stem cell growth conditions and four
commonly used GBM cell lines. Furthermore, we examined
whether RAD51 inhibition would affect the EZH2-mediated
enhanced repair of DSBs. Figure 7D shows the effects of EZH2
inhibition (using the specific EZH2 inhibitor GSK343) in combina-
tion with TMZ and the specific RAD51 inhibitor B02 (Huang et al.,
2011) on cell growth in two representative human GBM lines. In
contrast to TMZ treatment alone, EZH2 inhibition attenuated the
effect of TMZ. The enhanced proliferation could be reduced by
RAD51 inhibition (Figures 7D and S6B). In addition, reduced pro-
liferation of human glioblastoma cells through RAD51 inhibition
was dependent on the levels of EZH2 (Figure S6C). Next, we
treated human GBM lines with both EZH2 and RAD51 inhibitors
and found that this combination most effectively decreased glio-
blastoma proliferation (Figure S6D). Interestingly, glioma pa-
tients with high RAD51 expression do have a worse outcome
when compared with glioma patients with lower RAD51 levels
(Figure S6E). Finally, we performed immunofluorescence double
stainings for g-H2AX and 53BP1 to investigate whether the
observed changes in cell number upon addition of the different
compounds correlate with changes in DNA repair. Treatment
of primary tumor-derived human GBM cells with GSK343 and
TMZ resulted in a strongly reduced amount of g-H2AX and
53BP1 foci, indicating enhanced DNA damage repair. Uponell Identity upon Prolonged Ezh2 KD
ated, n = 9) versus controls (shEzh2 untreated, n = 2).
f n = 2) and Ezh2-depleted (mean of n = 9) tumors, isolated at the time of death.
h control tumors are shown in red, whereas significantly downregulated genes
egulated and downregulated, respectively.
enes upon Ezh2 KD in glioblastoma (threshold at p < 0.01).
control glioblastomas.
lioblastoma.
oblastoma.
epleted (n = 6) tumors. Data are normalized to HPRT.
glioblastomas.
tative Ezh2-depleted escaper tumors (#10 [=shEzh2_2] and #12 [=shEzh2_3]).
es in NSC conditions with or without doxycycline. ESCs were used as positive
-depleted GSCs 3 days after switching to ES conditions. Also shown are Ezh2
ns. ESCs were used as positive control (insert).
as positive control (insert).
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addition of the specific RAD51 inhibitor, DNA damage repair was
attenuated resulting in increased double-strand breaks as
shown by g-H2AX and 53BP1 foci (Figure 7E). In conclusion,
our data conclusively demonstrate that upon Ezh2 depletion in
high-grade glioma there is increased expression of DNA damage
response genes. This results in an increase in DNA damage
repair leading to a reduced sensitivity of glioblastoma cells for
chemotherapeutic drugs involved in DNA damage.
DISCUSSION
In agreement with previous results, we initially observed a
reduced tumor-initiating capacity upon Ezh2 depletion in glio-
blastoma (Suva` et al., 2009; Orzan et al., 2011). However, we
here demonstrate that prolonged Ezh2 depletion in glioblastoma
switches tumor cells to a different epigenetic state that signifi-
cantly changes tumor cell identity and results in tumor progres-
sion. This response is conserved in a variety of conventional hu-
man GBM cell lines and primary tumor-derived GBM stem cell
lines signifying the potential important consequences for thera-
peutic application of EZH2 inhibition. The observed escape
phenotype upon prolonged Ezh2 depletion is associated with a
dramatically modified differentiation status and DNA damage
response. These observations are supported by a recent study
showing that Ezh2 knockdown attenuated the ability of GSCs
to differentiate (Natsume et al., 2013).
Our data indicate that prolonged Ezh2 knockdown in malig-
nant glioma will epigenetically redirect tumor cells toward a
more undifferentiated, proliferative stem cell-like state by ex-
pressing many genes in common with ESCs. Of note, overex-
pressed levels of ES cell-associated genes have been detected
in GBM by immunohistochemistry (Guo et al., 2011; Holmberg
et al., 2011) and poorly differentiated human glioblastomas
with reduced PcG expression displayed overexpression of
genes that are normally enriched in ESCs but not expressed in
adult brain (Ben-Porath et al., 2008). Notably, this signature is
correlated with highly aggressive tumors and could be reversed
upon holding off Ezh2 depletion. Such Ezh2-mediated epige-
netic switching is different from regular cancer drug resistance
and forms an essential and novel tumor-resistance mechanism.
Chromatin immunoprecipitation on chip revealed that
H3K27me3 is the most significant chromatin mark that distin-
guishes somatic from induced pluripotent stem (iPS) epige-
nomes, leaving a central role for the PcG in induction of iPS.
Recent studies have shown the importance of PRC2 inactivationFigure 6. Key DNA Damage Repair Genes Are Induced upon Ezh2 Dep
(A) Heatmap showing differential expression of 142 known humanDNA repair gen
green, genes are depicted that are R1.5-fold upregulated, whereas red repres
showed increased average expression of DNA repair genes, as demonstrated b
(B) Half of the upregulated DNA repair genes upon Ezh2 KD is involved in HR. Show
to the average of 2 control tumors >1.5-fold enhanced, p < 0.01).
(C) Immunohistochemical staining for Rad51 in Ezh2 KD and control tumors (left).
PCR andwestern blot for Rad51 are shown. Error bars represent SDs for twoRad5
average of five control tumors.
(D) Histological analysis of Ezh2, Rad51, and g-H2AX upon Ezh2 KD in glioblastom
control tumors). Significance was determined using 12 samples per experimenta
(E) qRT-PCR of Rad51 and Ezh2 in shEzh2-depleted GICs (dox treatment of for 8,
Error bars represent SD for two sets of primers for each gene.
Cin reprogramming to ground-state pluripotency (Fragola et al.,
2013; Rais et al., 2013). This may explain why prolonged Ezh2
knockdown-mediated depletion of H3K27me3 is able to redirect
glioblastoma cells to an undifferentiated tumor status upon acti-
vation of the pluripotency network. Of note, NSCs already ex-
press the key reprogramming factors Sox2, Klf4, and c-Myc
and are reported to undergo rapid and efficient conversion to-
ward a pluripotent state (Silva et al., 2008). Subsequently, we
made useofGICs,which are Ink4a/Arf andp53deficient, two fac-
tors that have been shown to increase efficiency of reprogram-
ming upon depletion (Li et al., 2009; Kawamura et al., 2009).
Therefore, these cells may need less genetic manipulation to
dedifferentiate.
One key example of a gene enhanced upon Ezh2-depletion in
glioblastoma is the well-known reprogramming factor Lin28b,
which is highly expressed in several human cancers that are
poorly differentiated and have a worse prognosis (Viswanathan
et al., 2009). Recently, high levels of both Lin28A and Lin28B
were also observed in high-grade gliomas and associated with
invasiveness and proliferation (Mao et al., 2013). We also
observed that several mesenchymal markers were strongly
reduced upon Ezh2 depletion in glioblastoma, whereas epithelial
markers were upregulated. These results would suggest that
prolonged Ezh2 depletion mediates a mesenchymal-to-epithe-
lial transition. However, expression of the key epithelial marker
E-cadherin (Chd1) remained unaltered, and gene expression
levels of the key EMT inducers Snai1, Twist, and Klf8 were
enhanced. Most likely, these observations can be explained by
heterogeneous tumor cell populations upon prolonged Ezh2
depletion, which are each in a different state of epigenetic
switching or are trapped in an intermediate phenotype. As
Snai1 and Twist are also important mesoderm-inducing genes,
they may be activated in response to a complex integration of
signaling pathways. Recently, it has been shown that cellular
transition is a multifactorial process wherein series of stochastic
events must take place in order for somatic cells to undergo re-
programming into iPS (reviewed in Sancho-Martinez and Izpisua
Belmonte, 2013). Intriguingly, upon prolonged Ezh2 depletion in
glioblastoma, we observed differential expression of many of
these processes. Altogether, epigenetic remodeling in high-
grade glioma through prolonged Ezh2 knockdown leads to
dedifferentiation of glioblastoma cells, thereby enhancing tumor
cell plasticity and consequently tumor progression. The fact that
this modified tumor plasticity is reversible in GSCs with restored
Ezh2 levels implicates the direct role of Ezh2 in this process.letion in Glioblastoma
es in Ezh2-depleted tumors (n = 9) comparedwith control tumors (n = 2, right). In
ents R1.5-fold downregulation. Overall, eight of nine Ezh2-depleted tumors
y the barplot (left, error bars represent the SD).
n are the 15most strongly upregulated HR genes (average of 9 tumors relative
Shown are two representative tumors per experiment group. On the right, qRT-
1 primer pairs. Data are normalized toHPRT andmRNA levels are relative to the
a (left). Depicted are two representative examples for each group (Ezh2 KD and
l group (t test, right). Error bars represent the SD.
36, 72 and 96 hr) compared with untreated GICs. Data are normalized toHPRT.
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Interestingly, in addition, we found that key HR genes such as
Rad51were significantly enriched upon Ezh2 depletion in mouse
glioblastoma and seven human GBM cell lines. Consistent with
data in several other tumor types (Qiao et al., 2005; Le Scodan
et al., 2010), elevated RAD51 protein levels in glioblastoma are
correlated with worse outcome and resistance to DNA damage
by stimulating HR (Vispe´ et al., 1998). Decreased RAD51 levels
result in increased sensitivity to radiation and chemotherapeutic
drugs in glioma cells (Bao et al., 2006; Quiros et al., 2011). Previ-
ously, it has been shown that EZH2 recruits en binds to the
RAD51promoter (Changet al., 2011). Furthermore,PRC2 recruit-
ment to DNA damage sites has been reported, suggesting an
important role of PRC2 in modulating the DNA damage response
(Campbell et al., 2013; Chou et al., 2010). We demonstrate that
targeted inhibition of EZH2 resulted in enhanced expression of
DNA damage repair genes and consequently in enhanced DNA
DSB repair. Moreover, because TMZ sensitivity is depended on
the efficacy of DSB repair through HR (Tsaryk et al., 2006),
EZH2 inhibition also resulted in resistance to TMZ treatment.
Interestingly, ES and iPS cells have a high capacity for DSB repair
through HR by using RAD51 (Momcilovic et al., 2010), and HR
repair is decreased throughout differentiation toward neural pro-
genitors and astrocytes (Adams et al., 2010). Furthermore, a
recent study showed that efficient reprogramming requires key
HR genes, including Rad51 (Gonza´lez et al., 2013).
As abnormal epigenetic silencing is prevalent in cancers,
including glioma (Bruggeman et al., 2007), new therapeutic ap-
proaches are being developed to restore abnormally regulated
epigenomes. Target specificity is a major issue for epigenetic-
based therapy of cancer, and the consequences of this treat-
ment strategy may be broad. Recently, selective EZH2 inhibitors
have been described (reviewed in Helin and Dhanak, 2013).
Although there is an obvious rationale to use specific EZH2 inhib-
itors for clinical purposes, our data in human GBM cell lines indi-
cate that targeted EZH2 inhibition, especially when combined
with DNA damaging anticancer drugs, needs to be taken with
caution. Likely, EZH2 can act as an oncogene in certain cellular
contexts and as a tumor suppressor in others. Moreover, this
study indicates that the effect of EZH2 inhibition depends on
well-balanced drug administration schedules. It will be important
to extend the effects of EZH2 inhibitors, which are currently be-Figure 7. Ezh2-Mediated Enhanced DNA Repair Attenuates TMZ Effec
(A) Phase-contrast images and related cell growth of Ezh2 KD and control GICs tr
bars represent SD for three replicates. Significance was determined by unpaired
(B) At day 9 after intracranial injection with shEzh2 or shGFP transduced GICs, m
experimental groups (dox-treatment alone, dotted line, or a combination of dox
were treated with or without TMZ (once daily for 23 5 days, 100mg/kg orally). Kap
(right) are shown for each experimental group (n = 6 per group). A red line underne
rank test (Mantel-Cox).
(C) Rad51 mRNA levels in TMZ treated shEzh2 (± dox) tumors. Data are normali
(D) Phase-contrast images (left) of two representative human GBM cell lines G144
(1 or 10 mM, respectively), TMZ (100 mM), TMZ (10 mM) combinedwith GSK343 (1 o
RAD51 inhibitor B02 (10 mM, treatment with B02 alone is shown in Figure S6D). C
and E-98, right). Significance was determined by unpaired t testing (DMSO vers
TMZ+GSK343+B02, p = 0.04). Error bars represent the SD for the four cell lines.
(E) Immunofluorescent double stainings for g-H2AX and 53BP1 in G144GBMcells
3). DMSO-treated cells are shown as negative control. Irradiated G144 cells we
See also Figure S6.
Cing developed in human GBM using in vivo models and using
other associated driver mutations in future experiments. Since
short-term Ezh2 depletion results in a growth reduction without
the escaper phenomenon, it would be interesting to find new
drug dosing schedules combinations (for instance, EZH2 plus
RAD51 inhibition) thatmay keep tumors in growth arrest or cause
tumor cell death.
In conclusion, we show that prolonged Ezh2 depletion in
high-grade glioma results in a robust epigenetic switch causing
tumor progression. After a temporal proliferation arrest, pro-
longed Ezh2-depleted glioblastomas invariably escape and
dramatically change their tumor cell identity resulting in undiffer-
entiated and highly proliferative tumors. Moreover, EZH2 inhibi-
tion significantly enhances expression of key HR genes and
increased DNADSB repair, therebymodifying treatment efficacy
of TMZ. These results, together with the recent findings about
loss of function of EZH2 in tumorigenesis, have important impli-
cations for the use of EZH2 inhibitors in the clinic and demon-
strate that further careful investigation on the effects of EZH2 in-
hibition in glioblastoma is necessary before therapeutic
application in GBM patients.EXPERIMENTAL PROCEDURES
Tissue Isolation and Cell Culture
SVZ-derived NSCs were isolated from p53;Ink4a/Arf;Krasv12;LucR compound
conditional mice (7 days old; de Vries et al., 2010) and cultured in NSC-specific
serum-free medium supplemented with 20 ng/ml of both epidermal growth
factor and basic fibroblast growth factors (R&D Systems), as described before
inmore detail (Bruggeman et al., 2007). NSCswere grown adhesion free for the
first passages to eliminate non-sphere-forming cells. Using 5% fetal bovine
serum for 5 days, NSC differentiation was studied by plating 150,000 cells
onto poly-L-ornithine and laminin (pO/L) coated six-well plates. Next, cells
were grown adherent on pO/L plates and three times infected with lentiviral
CMV-Cre. Floxed, tumorigenic cells will be further referred as GICs. SVZ-
derived Ink4a/Arf/;EGFRvIIINSCswere generated and described previously
(Bruggeman et al., 2007). Mouse GSCs were isolated from spontaneous pri-
mary gliomas as previously described (de Vries et al., 2010) and cultured in
NSC conditions. Next, both GICs and GSCs were infected with a tet-inducible,
doxycycline-responsive short hairpin construct. After fluorescence-activated
cell sorting (FACS) for GFP (>96% positivity), cells were treated with or without
doxycycline (100 ng/ml) to obtain GFP or Ezh2 knockdown. Cell culture exper-
iments are described in the Supplemental Experimental Procedures.ts
eated with dox and TMZ (250 mM) or dimethylsulfoxide (DMSO) for 72 hr. Error
t testing using three biological triplicates per experimental group (right).
ice had the same tumor burden and were randomly divided into the different
and TMZ treatment, straight line). Mice received dox in the drinking water and
lan-Meier plots (left) and tumor growth measured by bioluminescence imaging
ath the x axis indicates the treatment periods. p values were determined by log-
zed to HPRT. Error bars represent SD for two sets of primers for each gene.
and U87-MG treated for 96 hr with DMSO, the specific EZH2 inhibitor GSK343
r 10 mM, respectively) or TMZ (10 mM) plusGSK343 (1 or 10 mM) and the specific
ell growth is shown for four different human GBM cell lines (G006, G144, U-87,
us TMZ, p = 0.02; TMZ versus TMZ+GSK343 p = 0.05; TMZ+GSK343 versus
upon addition of (combinations of) GSK343, TMZ, and BO2 (magnification is 63
re used as positive control (10 gray).
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Constructs, Virus Production, and Infections
For knockdown experiments, doxycycline-inducible FH1-tUTG-shGFP or
shEzh2 constructs were used (Herold et al., 2008). Lentivirus was generated
as described previously (de Vries et al., 2010), and cells were infected three
times for 6 hr.
Hairpins are listed in the Supplemental Experimental Procedures. All exper-
iments are performed using shEzh2_1 and repeated with shEzh2_2 and
shEzh2_3.
Stereotactic Intracranial Injections, Bioluminescence Imaging, and
Tumor Collection
A detailed description of the stereotactic brain injection and bioluminescence
procedures is described previously (de Vries et al., 2010). Mice were treated
with doxycycline hyclate (Sigma-Aldrich) administered at 2 mg/ml supple-
mented with 1% sucrose in the drinking water, maintained in darkened bottles
and refreshed twice weekly. TMZ was given orally (once daily 100 mg/kg for 2
3 5 days). The amount of bioluminescence in each animal was calculated rela-
tive to the first measurement when therapy was initiated. Animals were housed
and handled according to institutional guidelines and national regulations. All
animal experiments performed have been approved by the animal ethics com-
mittee of our institute.
Western Blot Analysis, Immunofluoresence, and
Immunohistochemistry
Western blot analysis and immunofluorescence were done as described
before (de Vries et al., 2010; Bruggeman et al., 2005). For immunohistochem-
ical stainings and antibodies, see Supplemental Information. Staining intensity
was scored as described in the Supplemental Experimental Procedures.
RNA Isolation and qRT-PCR
Total RNAwas extracted using TRIzol Reagent (Invitrogen). cDNAwas synthe-
sized from 1ug total RNA with the Quantiscript Reverse Transriptase Kit
(QIAGEN). qRT-PCR was performed as described before (Bruggeman et al.,
2007). Input cDNA concentrations were normalized to murine HPRT and actin.
For primer sequences, see the Supplemental Information.
RNA Sequencing
RNA sequencing (RNA-seq) analysis was performed on Ezh2-depleted
(shEzh2 +dox, n = 9) and control tumors (shEzh2 no dox, n = 2, p53;Ink4a/
Arf;Krasv12 background). Sequencing by synthesis (50–175 bp) was performed
using the Illumina Hiseq2000 platforms according to standard protocols
(Illumina). Data analysis was performed using R (www.r-project.org) and
Bioconductor (www.bioconductor.org). Limma’s Voom was used for normali-
zation. For a detailed description of the RNA-seq analysis, see the Supple-
mental Experimental Procedures.
ACCESSION NUMBERS
The NCBI GEO accession number for the RNA-seq analyses performed on
Ezh2-depleted and control tumors reported in this paper is GSE63853.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
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